CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy.
Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
过去 30 年来，新诊断多发性骨髓瘤（NDMM）患者采用大剂量美法仑（HDM）预处理后进行自体干细胞移植（ASCT），已成为一线治疗核心方案。诱导治疗、HDM-ASCT，随后进行巩固及维持治疗，构成当前多发性骨髓瘤（MM）治疗的基本框架。达雷妥尤单抗和艾沙妥昔单抗等抗 CD38 单克隆抗体的引入改变了适合移植的 NDMM 患者治疗模式，四联方案已成为新的标准诱导治疗。随着嵌合抗原受体（CAR）T 细胞和双特异性抗体（BsAb）等强效新型免疫疗法问世，MM 治疗格局正在发生变革；这些疗法目前用于复发/难治性 MM（RRMM），并已在 NDMM 中开展试验。本综述聚焦于免疫疗法纳入适合 ASCT 的 NDMM 患者治疗方案的现状。
Upfront high-dose therapy with melphalan (HDM) followed by autologous stem cell transplantation (ASCT) has established itself as a core treatment for newly diagnosed multiple myeloma (NDMM) patients in the past 30 years. Induction therapy, HDM-ASCT, and subsequent consolidation and maintenance therapy comprise the current fundamental framework for MM treatment. The introduction of anti-CD38 monoclonal antibodies such as daratumumab and isatuximab has changed the treatment paradigm for transplant-eligible NDMM patients in that quadruplets have become the new standard induction therapy.
The treatment landscape of MM is undergoing a transformative shift with the introduction of potent new immunotherapies, such as chimeric antigen receptor (CAR)-T cells and bispecific antibodies (BsAbs), which are currently used in the relapsed/refractory setting (RRMM) and are already being tested in the NDMM. This review will focus on the incorporation of immunotherapy in the treatment scenario of NDMM patients eligible for ASCT.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
